Balyasny Asset Management
TEVA icon

Balyasny Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Balyasny Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-285,500
Closed -$8.91M – 3513
2025
Q4 		$8.91M Buy
285,500
+265,300
+1,313% +$6.54M 0.01% 1080
2025
Q3 		$408K Buy
+20,200
New +$355K ﹤0.01% 2470
2025
Q1 		– Sell
-11,700
Closed -$258K – 3276
2024
Q4 		$258K Sell
11,700
-22,300
-66% -$406K ﹤0.01% 2452
2024
Q3 		$613K Buy
+34,000
New +$595K ﹤0.01% 2183
2017
Q3 		– Sell
-200,000
Closed -$6.64M – 2092
2017
Q2 		$6.64M Buy
+200,000
New +$6.19M 0.03% 670
2017
Q1 		– Sell
-456,200
Closed -$16.5M – 1781
2016
Q4 		$16.5M Buy
+456,200
New +$18.2M 0.09% 328
2016
Q3 		– Sell
-400,000
Closed -$20.1M – 1262
2016
Q2 		$20.1M Buy
400,000
+325,000
+433% +$17.3M 0.13% 210
2016
Q1 		$4.01M Buy
+75,000
New +$4.4M 0.02% 588
2013
Q4 		– Sell
-125,000
Closed -$9.24M – 629
2013
Q3 		$9.24M Buy
+125,000
New +$4.88M 0.12% 225

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's TEVA Position: Q2 2025 in Review

Balyasny Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 28,613 shares — an estimated $440K sold.

Balyasny Asset Management first reported a position in TEVA in Q2 2013 and held it in 31 quarters. The position peaked at $223M in Q4 2015. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Balyasny Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 28,613 Teva Pharmaceuticals shares in Q2 2025, an estimated $440K.
  • Balyasny Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Balyasny Asset Management's Teva Pharmaceuticals position peaked at $223M in Q4 2015.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.